NCT03312023View on ClinicalTrials.gov

Ledipasvir/Sofosbuvir for Hepatitis B Virus Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

February 1, 2018

Primary Completion Date

August 10, 2020

Study Completion Date

June 30, 2021

Conditions
Hepatitis B
Interventions
DRUG

Ledipasvir 90 MG / Sofosbuvir 400 MG Oral Tablet [Harvoni]

1 pill once daily for 12 weeks for Group A

DRUG

Sofosbuvir 400 MG [Sovaldi]

1 pill once daily for 12 weeks for Group C

DRUG

Ledipasvir 90 MG

1 pill once daily for 12 weeks for Group D

Trial Locations (1)

21201

Institute of Human Virology (IHV), University of Maryland Baltimore, Baltimore

Sponsors

Collaborators (1)

Gilead Sciences
All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

lead

University of Maryland, Baltimore

OTHER